Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine

Vaccine

Volumn 33, Issue 4, 2015, Pages 568-576

  Sundararajan, Aarthi ^a,g   Sangster, Mark Y ^a   Frey, Sharon ^b   Atmar, Robert L ^c   Chen, Wilbur H ^d   Ferreira, Jennifer ^e   Bargatze, Robert ^f   Mendelman, Paul M ^f   Treanor, John J ^a   Topham, David J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e EMMES CORPORATION   (United States)

^f Takeda Vaccines (Montana) Inc   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; B cell; Mucosal; Norovirus; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR10; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; L SELECTIN; NOROVIRUS VACCINE; PHOSPHORYL LIPID A; SYNDECAN 1; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PLACEBO; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALE; NOROVIRUS; NOROVIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ANIMAL; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MUCOSAL IMMUNITY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NOROVIRUS; PLACEBOS; TREATMENT OUTCOME; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; YOUNG ADULT;

EID: 84920589100     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.073     Document Type: Article

References (37)

1. Bresee J.S., Widdowson M.A., Monroe S.S., Glass R.I. Foodborne viral gastroenteritis: challenges and opportunities. Clin Infect Dis 2002, 35:748-753.
2. Widdowson M.A., Sulka A., Bulens S.N., Beard R.S., Chaves S.S., Hammond R., et al. Norovirus and foodborne disease, United States, 1991-2000. Emerg Infect Dis 2005, 11:95-102.
3. Hall A.J., Lopman B.A., Payne D.C., Patel M.M., Gastanaduy P.A., Vinje J., et al. Norovirus disease in the United States. Emerg Infect Dis 2013, 19:1198-1205.
4. Mead P.S., Slutsker L., Dietz V., McCaig L.F., Bresee J.S., Shapiro C., et al. Food-related illness and death in the United States. Emerg Infect Dis 1999, 5:607-625.
5. Koo H.L., Ajami N., Atmar R.L., DuPont H.L. Noroviruses: the leading cause of gastroenteritis worldwide. Discov Med 2010, 10:61-70.
6. Hall A.J., Vinjé J., Lopman B., Park G.W., Yen C., Gregoricus N., et al. Updated norovirus outbreak management and disease prevention guidelines. Morb Mortal Wkly Rep 2011, 60:1-15.
7. Teunis P.F., Moe C.L., Liu P., Miller S.E., Lindesmith L., Baric R.S., et al. Norwalk virus: how infectious is it?. J Med Virol 2008, 80:1468-1476.
8. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010, 9:299-307.
9. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011, 365:2178-2187.
10. Hutson A.M., Atmar R.L., Marcus D.M., Estes M.K. Norwalk virus-like particle hemagglutination by binding to H histo-blood group antigens. J Virol 2003, 77:405-415.
11. Reeck A., Kavanagh O., Estes M.K., Opekun A.R., Gilger M.A., Graham D.Y., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010, 202:1212-1218.
12. Baric R.S., Yount B., Lindesmith L., Harrington P.R., Greene S.R., Tseng F.C., et al. Expression and self-assembly of Norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol 2002, 76:3023-3030.
13. El-Kamary S.S., Pasetti M.F., Mendelman P.M., Frey S.E., Bernstein D.I., Treanor J.J., et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010, 202:1649-1658.
14. Velasquez L.S., Shira S., Berta A.N., Kilbourne J., Medi B.M., Tizard I., et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011, 29:5221-5231.
15. Mason H.S., Herbst-Kralovetz M.M. Plant-derived antigens as mucosal vaccines. Curr Top Microbiol Immunol 2012, 354:101-120.
16. Ball J.M., Hardy M.E., Atmar R.L., Conner M.E., Estes M.K. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998, 72:1345-1353.
17. Chachu K.A., LoBue A.D., Strong D.W., Baric R.S., Virgin H.W. Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog 2008, 4:e1000236.
18. Harrington P.R., Yount B., Johnston R.E., Davis N., Moe C., Baric R.S. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 2002, 76:730-742.
19. Lindesmith L.C., Donaldson E., Leon J., Moe C.L., Frelinger J.A., Johnston R.E., et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010, 84:1800-1815.
20. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Estes M.K. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003, 108:241-247.
21. Zhu S., Regev D., Watanabe M., Hickman D., Moussatche N., Jesus D.M., et al. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. PLoS Pathog 2013, 9:e1003592.
22. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997, 22:219-225.
23. Jarrett W.F., O'Neil B.W., Gaukroger J.M., Laird H.M., Smith K.T., Campo M.S. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec 1990, 126:449-452.
24. Krul M.R., Tijhaar E.J., Kleijne J.A., Van Loon A.M., Nievers M.G., Schipper H., et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996, 43:44-48.
25. Liu X.S., Abdul-Jabbar I., Qi Y.M., Frazer I.H., Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998, 252:39-45.
26. Rackow E.C., Astiz M.E., Kim Y.B., Weil M.H. Monophosphoryl lipid A blocks the hemodynamic effects of lethal endotoxemia. J Lab Clin Med 1989, 113:112-117.
27. Tagliabue A., Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008, 4:347-349.
28. Sangster M.Y., Baer J., Santiago F.W., Fitzgerald T., Ilyushina N.A., Sundararajan A., et al. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol 2013, 20:867-876.
29. He X.S., Sasaki S., Baer J., Khurana S., Golding H., Treanor J.J., et al. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis 2013, 207:288-296.
30. Treanor J.J., Atmar R.L., Frey S.E., Gormley R., Chen W.H., Ferreira J., et al. A novel intramuscular bivalent norovirus VLP vaccine candidate - reactogenicity, safety and immunogenicity in a phase I trial in healthy adults. J Infect Dis 2014, 210(11):1763-1771.
31. Avery D.T., Ellyard J.I., Mackay F., Corcoran L.M., Hodgkin P.D., Tangye S.G. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 2005, 174:4034-4042.
32. O'Connell F.P., Pinkus J.L., Pinkus G.S. C.D138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 2004, 121:254-263.
33. Mackay C.R., Marston W.L., Dudler L., Spertini O., Tedder T.F., Hein W.R. Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. Eur J Immunol 1992, 22:887-895.
34. Bull R.A., Tu E.T., McIver C.J., Rawlinson W.D., White P.A. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. J Clin Microbiol 2006, 44:327-333.
35. Jaimes M.C., Rojas O.L., Kunkel E.J., Lazarus N.H., Soler D., Butcher E.C., et al. Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 2004, 78:10967-10976.
36. Crompton P.D., Mircetic M., Weiss G., Baughman A., Huang C.Y., Topham D.J., et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 2009, 182:3318-3326.
37. Halliley J.L., Kyu S., Kobie J.J., Walsh E.E., Falsey A.R., Randall T.D., et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 2010, 28:3582-3587.